Rozlytrek® (entrectinib)
for Lung Cancer

Rozlytrek (entrectinib) is an oral kinase inhibitor used to treat adults with metastatic ROS1-positive non-small cell lung cancer (NSCLC). It’s also approved under accelerated approval for adults and children 1 month and older with solid tumors that have NTRK gene fusions, when surgery isn’t an option or other treatments have failed. Rozlytrek targets and blocks ROS1 fusion proteins to help stop cancer cell growth and spread.

Heart